Clinical Effects of T790M Mutation in EGFR Tyrosine Kinase
Inhibitor Resistant NSCLC Patients

INTRODUCTION: To compare patient characteristics between the T790M-positive and T790M-negative populations, and to analyze the post-progression survival (PPS) after initial tyrosine kinase inhibitor (TKI) failure in order to investigate the prognosis in patients undergoing rebiopsy. METHODS: We investigated the patient characteristics, including the initial EGFR-TKI response and T790M status at the time of rebiopsy or liquid biopsy, subsequent treatment after resistance to the initial EGFR-TKI (the presence of EGFR-TKI re-challenge), treatment just before biopsy and/or rebiopsy (EGFR-TKIs or chemotherapy), the timing of the rebiopsy (just after the initial EGFR-TKI failure or others). RESULTS: No difference was found between the two groups with T790M mutation positive and negative in terms of age, gender, and metastasis location. Only patients with positive T790M mutation had higher progression after TKI use compared to negative ones (p: 0.000). The progression-free median survival in patients using TKI was 19.33 months in the group with T790M mutation and 22.25 months in the negative group. Overall survival was found to be 75 months and 27.5 months in the T790M positive and negative group, respectively, and this was statistically significant. (p: 0.009). DISCUSSION AND CONCLUSION: Overall survival was significantly longer in the T790M positive group than in the T790M negative group. In addition, liquid biopsy can be performed several times for patients with progression after EGFR-TKI use and who do not want to undergo tissue biopsy

Anahtar Kelime:

EGFR Tirozin Kinaz İnhibitörlerine Dirençli KHDAK Hastalarında T790M Mutasyonunun Klinik Etkileri

Öz:

GİRİŞ ve AMAÇ: T790M - pozitif ve T790M - negatif popülasyonlar arasındaki hasta özellikleri karşılaştırıldı ve ilk tirozin kinaz inhibitörü (TKI) başarısızlığından sonra progresyon sonrası sağkalım (PPS) analiz edilerek yeniden biyopsi yapılan hastalarda prognoz araştırıldı. YÖNTEM ve GEREÇLER: Hastaların karakteristik özellikleri, EGFR-TKI yanıtı, rebiyopsi veya likit biyopsi sırasındaki EGFR durumu, rebiyopsi öncesi uygulanan tedavi (kemoterapi/ EGFR-TKI), ilk EGFR-TKI’a direnç geliştikten sonraki tedavi ve biyopsi zamanı (ilk EGFR-TKI başarısızlığı sonrası) araştırılmıştır. BULGULAR: T790M mutasyonu pozitif ve negatif olan iki grup arasında yaş, cinsiyet ve metastaz yeri arasında fark saptanmadı. Yalnızca T790M mutasyonu pozitif olan hastalarda TKİ kullanımı sonrası progresyonun negatif olanlara göre daha fazla olduğu görüldü (p: 0.001). TKİ kullanan hastalarda progresyonsuz median sağkalım T790M mutasyonu olan grupta 19,33 ay iken negative olan grupta 22.25 ay olarak saptandı. Genel sağkalım T790M pozitif ve negative olan grupta sırasıyla 75 ay ve 27,5 ay olarak bulundu ve bu istatistiksel olarak anlamlı idi (p: 0.009). TARTIŞMA ve SONUÇ: Genel sağkalım T790M pozitif grupta,T790M negatif gruba göre istatistiksel olarak anlamlı düzeyde uzun olarak saptandı. Ayrıca EGFR-TKI kullanımı sonrası progresyon olan ve doku biyopsisi yaptırmak istemeyen hastalara likit biyopsisinin birkaç kez yapılabilir.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

Sağlık Bilimleri Üniversitesi, Doktor Suat Seren Göğüs Hastalıkları ve Göğüs Cerrahisi Eğitim ve Araştırma Hastanesi, Göğüs Hastalıkları Anabilim Dalı, İzmir, Türkiye
1. Fukuoka M, Wu Y-L, Thongprasert S, Sunpaweravong P, Leong S-S, Sriuranpong V, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, firstline study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced nonesmall-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011; 29: 2866-74. https://doi.org/10.1200/JCO.2010.33.4235
2. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009; 361: 958-67. https://doi.org/10.1056/NEJMoa0904554
3. Mok TS, Wu Y-L, Thongprasert S,YangC-H, Chu D-T, Saijo N, et al. Gefitinib or carboplatinepaclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361:947-57. https://doi.org/10.1056/NEJMoa0810699
4. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba I, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005; 97: 339-46. https://doi.org/10.1093/jnci/dji055
5. Wu Y-L, Zhou C, Hu C-P, Feng J, Lu S, Huang Y, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment ofAsian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014; 15: 213-22. https://doi.org/10.1016/S1470-2045(13)70604-1
6. Jackman D, Pao W, Riely GJ, Kris MG, Jänne PA, Lynch T, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in nonesmall-cell lung cancer. J Clin Oncol. 2010; 28: 357-60. https://doi.org/10.1200/JCO.2009.24.7049
7. Park K, Tan E-H, O’Byrne K, Zhang L, Boyer M, Moket T, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016; 17: 577-89. https://doi.org/10.1016/S1470-2045(16)30033-X
8. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, TurkeAB, Fidias P, et al. Genotypic and histologicalevolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011; 3: 75ra26. https://doi.org/10.1126/scitranslmed.3002003
9. Yun C-H, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A. 2008; 105: 2070-5. https://doi.org/10.1073/pnas.0709662105
10. Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFRmutant lung cancers. Clin Cancer Res. 2013; 19: 2240-7 https://doi.org/10.1158/1078-0432.CCR-12-2246
11. Sacher AG, Komatsubara KM, Oxnard GR. Application of plasma genotyping technologies in nonesmall cell lung cancer: a practical review. J Thorac Oncol 2017; 12: 1344-56. https://doi.org/10.1016/j.jtho.2017.05.022
12. Rolfo C, Mack PC, Scagliotti GV, Baas P, Barlesi F, Bivona TG, et al. Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC. J Thorac Oncol. 2018; 13: 1248-68. https://doi.org/10.1016/j.jtho.2018.05.030
13. Hata A, Katakami N, Yoshioka H, Takeshita J, Tanaka K, Nanjo S, et al. Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor. Cancer. 2013; 119: 4325- 32. https://doi.org/10.1002/cncr.28364
14.Ji W, Choi CM, Rho JK, Jang SJ, Park YS, Chun S-M, et al. Mechanisms of acquired resistance to EGFRtyrosine kinase inhibitor in Korean patients with lung cancer. BMC Cancer. 2013; 13: 606. https://doi.org/10.1186/1471-2407-13-606
15. Tseng JS, Su KY, Yang TY, Chen K-C, Hsu K-H, Chen H-Y et al. The emergence of T790M mutation in EGFRmutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and longterm existence of T790M. Oncotarget. 2016; 7: 48059-69. https://doi.org/10.18632/oncotarget.10351
16. Nosaki K, Satouchi M, Kurata T, Yoshida T, Okamoto I, Katakami N, et al. Re-biopsy status among non-small cell lung cancer patients in Japan: a retrospective study. Lung Cancer. 2016; 101: 1-8. https://doi.org/10.1016/j.lungcan.2016.07.007
17. Oya Y, Yoshida T, Kuroda H, Shimizu J, Horio Y, Sakao Y, et al. Association between EGFR T790M status and progression patterns during initial EGFR-TKItreatment in patients harboring EGFR mutation. Clin Lung Cancer 2017; 18: 698-705.e2. https://doi.org/10.1016/j.cllc.2017.05.004
18. Ke EE, Zhou Q, Zhang QY, Su J, Chen Z-H, Zhang X-C, et al. A higher proportion of the EGFR T790M mutation may contribute to the bettersurvival of patients with exon 19 deletions compared with those with L858R. J Thorac Oncol. 2017; 12: 1368-75. https://doi.org/10.1016/j.jtho.2017.05.018
19. Kaburagi T, Kiyoshima M, Nawa T, Ichimura H, Saito T, Hayashihara K, et al. Acquired EGFR T790M mutation after relapse following EGFR-TKI therapy: a population-based multi-institutional study. Anticancer Res. 2018; 38: 3145-50. https://doi.org/10.21873/anticanres.12577
20. MasoAD, Lorenzi M, Roca E, Pilotto S, Macerelli M, Polo V, et al. Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Nonesmall-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy. Clinical Lung Cancer. 2020; 21(1): 1-14.e3. https://doi.org/10.1016/j.cllc.2019.07.009
21. Thress KS, Brant R, Carr TH, Dearden S, Jenkins S, Brown H, et al. EGFR mutation detection in ctDNA from NSCLC patient plasma: A crossplatform comparison of leading technologies to support the clinical development of AZD9291. Lung Cancer. 2015; 90: 509-515. https://doi.org/10.1016/j.lungcan.2015.10.004
22. Sueoka-Aragane N, Katakami N, Satouchi M, Yokota S, Aoe K, Iwanaga K, et al. Monitoring EGFR T790M with plasma DNA from lung cancer patients in a prospective observational study. Cancer Sci. 2016; 107: 162-167. https://doi.org/10.1111/cas.12847
23. Zheng D, Ye X, Zhang MZ, Sun Y, Wang JY, Ni J, et al. Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance. Sci Rep. 2016; 6: 20913. https://doi.org/10.1038/srep20913
24.Jenkins S, Yang JC, Ramalingam SS, Yu K, Patel S, Weston S, et al. Plasma ctDNA analysis for detection of the EGFR T790M mutation in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2017; 12: 1061-1070. https://doi.org/10.1016/j.jtho.2017.04.003
25. Tanaka K, Nosaki K, Otsubo K, Azuma K, Sakata S, Ouchi H, et al.Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor-naïve patients with non-small cell lung cancer harboring EGFR mutations. Oncotarget. 2017; 8: 68123-68130. https://doi.org/10.18632/oncotarget.19243
26. Planchard D, Popat S, Kerr K, Novello S, Smit EF, FaivreFinn, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018; 29(Suppl 4): iv192-237. https://doi.org/10.1093/annonc/mdy275
27. Oxnard GR, Arcila ME, Sima CS, Riely GJ, Chmielecki J, Kris MG, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res. 2011; 17:1616-22 https://doi.org/10.1158/1078-0432.CCR-10-2692
28. Hata A, Katakami N, Yoshioka H, Kaji R, Masago K, Fujita S, et al. Spatiotemporal T790M heterogeneity in a patient with EGFR-mutant non-small-cell lung cancer. J Thorac Oncol. 2014; 9(8): 64-5. https://doi.org/10.1097/JTO.0000000000000255

APA	GÜLDAVAL F, ANAR C, Büyükşirin M, Ayık Türk M, GAYAF M, Akyol M, ALICI İ, Polat G, Karadeniz G, AYRANCI A, DEMİRCİ ÜÇSULAR F, Erdogan K, Kutbay Y, Arikan S, batum ö, Komurcuoglu B, ERMİN S, Balcı G (2021). Clinical Effects of T790M Mutation in EGFR Tyrosine Kinase Inhibitor Resistant NSCLC Patients . , 51 - 56. 10.5505/KTD.2021.82856
Chicago	GÜLDAVAL FİLİZ,ANAR Ceyda,Büyükşirin Melih,Ayık Türk Merve,GAYAF MİNE,Akyol Murat,ALICI İbrahim Onur,Polat Gulru,Karadeniz Gülistan,AYRANCI AYSU,DEMİRCİ ÜÇSULAR FATMA,Erdogan Kadri Murat,Kutbay Yasar,Arikan Sener,batum özgür,Komurcuoglu Berna,ERMİN SİNEM,Balcı Günseli Clinical Effects of T790M Mutation in EGFR Tyrosine Kinase Inhibitor Resistant NSCLC Patients . (2021): 51 - 56. 10.5505/KTD.2021.82856
MLA	GÜLDAVAL FİLİZ,ANAR Ceyda,Büyükşirin Melih,Ayık Türk Merve,GAYAF MİNE,Akyol Murat,ALICI İbrahim Onur,Polat Gulru,Karadeniz Gülistan,AYRANCI AYSU,DEMİRCİ ÜÇSULAR FATMA,Erdogan Kadri Murat,Kutbay Yasar,Arikan Sener,batum özgür,Komurcuoglu Berna,ERMİN SİNEM,Balcı Günseli Clinical Effects of T790M Mutation in EGFR Tyrosine Kinase Inhibitor Resistant NSCLC Patients . , 2021, ss.51 - 56. 10.5505/KTD.2021.82856
AMA	GÜLDAVAL F,ANAR C,Büyükşirin M,Ayık Türk M,GAYAF M,Akyol M,ALICI İ,Polat G,Karadeniz G,AYRANCI A,DEMİRCİ ÜÇSULAR F,Erdogan K,Kutbay Y,Arikan S,batum ö,Komurcuoglu B,ERMİN S,Balcı G Clinical Effects of T790M Mutation in EGFR Tyrosine Kinase Inhibitor Resistant NSCLC Patients . . 2021; 51 - 56. 10.5505/KTD.2021.82856
Vancouver	GÜLDAVAL F,ANAR C,Büyükşirin M,Ayık Türk M,GAYAF M,Akyol M,ALICI İ,Polat G,Karadeniz G,AYRANCI A,DEMİRCİ ÜÇSULAR F,Erdogan K,Kutbay Y,Arikan S,batum ö,Komurcuoglu B,ERMİN S,Balcı G Clinical Effects of T790M Mutation in EGFR Tyrosine Kinase Inhibitor Resistant NSCLC Patients . . 2021; 51 - 56. 10.5505/KTD.2021.82856
IEEE	GÜLDAVAL F,ANAR C,Büyükşirin M,Ayık Türk M,GAYAF M,Akyol M,ALICI İ,Polat G,Karadeniz G,AYRANCI A,DEMİRCİ ÜÇSULAR F,Erdogan K,Kutbay Y,Arikan S,batum ö,Komurcuoglu B,ERMİN S,Balcı G "Clinical Effects of T790M Mutation in EGFR Tyrosine Kinase Inhibitor Resistant NSCLC Patients ." , ss.51 - 56, 2021. 10.5505/KTD.2021.82856
ISNAD	GÜLDAVAL, FİLİZ vd. "Clinical Effects of T790M Mutation in EGFR Tyrosine Kinase Inhibitor Resistant NSCLC Patients ". (2021), 51-56. https://doi.org/10.5505/KTD.2021.82856

APA	GÜLDAVAL F, ANAR C, Büyükşirin M, Ayık Türk M, GAYAF M, Akyol M, ALICI İ, Polat G, Karadeniz G, AYRANCI A, DEMİRCİ ÜÇSULAR F, Erdogan K, Kutbay Y, Arikan S, batum ö, Komurcuoglu B, ERMİN S, Balcı G (2021). Clinical Effects of T790M Mutation in EGFR Tyrosine Kinase Inhibitor Resistant NSCLC Patients . Kocaeli Tıp Dergisi, 10(2), 51 - 56. 10.5505/KTD.2021.82856
Chicago	GÜLDAVAL FİLİZ,ANAR Ceyda,Büyükşirin Melih,Ayık Türk Merve,GAYAF MİNE,Akyol Murat,ALICI İbrahim Onur,Polat Gulru,Karadeniz Gülistan,AYRANCI AYSU,DEMİRCİ ÜÇSULAR FATMA,Erdogan Kadri Murat,Kutbay Yasar,Arikan Sener,batum özgür,Komurcuoglu Berna,ERMİN SİNEM,Balcı Günseli Clinical Effects of T790M Mutation in EGFR Tyrosine Kinase Inhibitor Resistant NSCLC Patients . Kocaeli Tıp Dergisi 10, no.2 (2021): 51 - 56. 10.5505/KTD.2021.82856
MLA	GÜLDAVAL FİLİZ,ANAR Ceyda,Büyükşirin Melih,Ayık Türk Merve,GAYAF MİNE,Akyol Murat,ALICI İbrahim Onur,Polat Gulru,Karadeniz Gülistan,AYRANCI AYSU,DEMİRCİ ÜÇSULAR FATMA,Erdogan Kadri Murat,Kutbay Yasar,Arikan Sener,batum özgür,Komurcuoglu Berna,ERMİN SİNEM,Balcı Günseli Clinical Effects of T790M Mutation in EGFR Tyrosine Kinase Inhibitor Resistant NSCLC Patients . Kocaeli Tıp Dergisi, vol.10, no.2, 2021, ss.51 - 56. 10.5505/KTD.2021.82856
AMA	GÜLDAVAL F,ANAR C,Büyükşirin M,Ayık Türk M,GAYAF M,Akyol M,ALICI İ,Polat G,Karadeniz G,AYRANCI A,DEMİRCİ ÜÇSULAR F,Erdogan K,Kutbay Y,Arikan S,batum ö,Komurcuoglu B,ERMİN S,Balcı G Clinical Effects of T790M Mutation in EGFR Tyrosine Kinase Inhibitor Resistant NSCLC Patients . Kocaeli Tıp Dergisi. 2021; 10(2): 51 - 56. 10.5505/KTD.2021.82856
Vancouver	GÜLDAVAL F,ANAR C,Büyükşirin M,Ayık Türk M,GAYAF M,Akyol M,ALICI İ,Polat G,Karadeniz G,AYRANCI A,DEMİRCİ ÜÇSULAR F,Erdogan K,Kutbay Y,Arikan S,batum ö,Komurcuoglu B,ERMİN S,Balcı G Clinical Effects of T790M Mutation in EGFR Tyrosine Kinase Inhibitor Resistant NSCLC Patients . Kocaeli Tıp Dergisi. 2021; 10(2): 51 - 56. 10.5505/KTD.2021.82856
IEEE	GÜLDAVAL F,ANAR C,Büyükşirin M,Ayık Türk M,GAYAF M,Akyol M,ALICI İ,Polat G,Karadeniz G,AYRANCI A,DEMİRCİ ÜÇSULAR F,Erdogan K,Kutbay Y,Arikan S,batum ö,Komurcuoglu B,ERMİN S,Balcı G "Clinical Effects of T790M Mutation in EGFR Tyrosine Kinase Inhibitor Resistant NSCLC Patients ." Kocaeli Tıp Dergisi, 10, ss.51 - 56, 2021. 10.5505/KTD.2021.82856
ISNAD	GÜLDAVAL, FİLİZ vd. "Clinical Effects of T790M Mutation in EGFR Tyrosine Kinase Inhibitor Resistant NSCLC Patients ". Kocaeli Tıp Dergisi 10/2 (2021), 51-56. https://doi.org/10.5505/KTD.2021.82856